Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

 Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

Alnylam Reports Positive Result of Givosiran in P-III ENVISION Study for Acute Hepatic Porphyria (AHP)

Shots:

  • The P-III ENVISION study involves assessing of Givosiran vs PBO in 94 patients with AHP including patients with acute intermittent porphyria (AIP) across 18 countries in ratio 1:1             
  • The ENVISION study resulted in meeting 1EPs & 2EPs i.e, reduction in porphyria attacks, presented at EASL on 13 Apr,2019 with its expected NDA & MAA filing in H2’19
  • Givosiran (SC, 2.5mg/kg/mo) is a RNAi therapeutics, based on Alnylam’s Enhanced Stabilization Chemistry ESC-GalNAc conjugate technology. It has received FDA’s BT & EMA’s PRIME designation and ODD in both, the US & EU

Click here to read full press release/ article | Ref: Alnylam | Image: FDA Headlines

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post